Search

everythinglearnresearchcommunity

for

Search:↓

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

A user shared progress pictures after 5 months of using oral Minoxidil (2.5mg) and Finasteride (1mg) for hair loss, reporting satisfaction with the results despite some light spots. Another user suggested increasing the Minoxidil dose if needed after a year.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

User experienced scarring from microneedling at fast speed and paused treatment for 3-4 weeks to recover. Advice given includes waiting a full month for recovery to avoid scars.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

The conversation is about determining which type of Saw Palmetto, either Chamaerops humilis or Serenoa repens, is effective for inhibiting the 5 alpha reductase enzyme related to hair loss. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

The post discusses using Sandalore as a potential hair loss treatment, emphasizing precise measurements and safe handling. The user compares Sandalore's effects to Minoxidil and mentions preparing a solution with ethanol and DMSO.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

User is seeking information on obtaining dutasteride vials for mesotherapy in the US, mentioning a closed source and lack of local clinic options.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The user plans to switch to oral finasteride and oral minoxidil due to insufficient results from PRP, topical minoxidil, and mild DHT inhibitors. They seek advice on purchasing these medications from My.India, questioning its trustworthiness.

The user is seeking a way to obtain 5mg finasteride in Germany, as local dermatologists refuse to prescribe it. They are considering online options but have only found 1mg pills available.

The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.

User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.

The user tried Redensyl but stopped using topical finasteride and continued with 5% minoxidil. They are experiencing hair loss and considering accepting baldness.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

A 25-year-old shared progress after a year using oral finasteride, topical minoxidil, and microneedling, noting significant hair improvement despite periodic shedding. The user experienced body hair loss as a side effect but reported no other issues and plans to continue the treatment.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user experienced significant hair regrowth using oral finasteride 1.25mg daily and a Capillus RX laser cap, with no side effects. Improvement was noticed after 9 months, and shedding stopped after the initial 4-5 months.

The user has been using finasteride for four years and topical minoxidil with microneedling for a year but has not seen significant results in slowing hair loss. They are considering trying dutasteride despite concerns about its intensity, and others suggest trying oral minoxidil or combining treatments for better results.

A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.

A user shared their 1.5-year experience using 0.25mg finasteride daily for hair loss, noting significant hair quality improvements and reduced scalp itch but mild erectile dysfunction. They managed side effects with daily 2.5mg Cialis and 5mg citrulline and plan to continue this routine.

A user shared their experience with a 7600 graft hair transplant using scalp, beard, and chest hair over three procedures, expressing satisfaction with the results despite mixed feedback. They also used finasteride to thicken hair and considered scalp micropigmentation for further improvement.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

The conversation discusses the benefits of electric toothbrushes for oral health, highlighting the Philips Sonicare Protective Clean 5300 and Oral-B Pro 1000 as top choices for effective plaque removal and gum care. Both toothbrushes are recommended for their reliability, with the Philips being budget-friendly and the Oral-B offering advanced features for sensitive teeth.

A user is using finasteride, minoxidil, and a dermastamp for hair regrowth. They report itchy scalp but see positive results.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.